Retatrutide Weekly Update

AnalysisCBS News investigation: two FAERS death reports and a near-doubling of poison-centre exposures tied to products sold as retatrutide

A CBS News investigation, published October 13, 2026, reported that the US Food and Drug Administration has received two reports of deaths in 2026 among people who had taken products sold as retatrutide, both filed through the FDA Adverse Event Reporting System (FAERS) — a database that primarily monitors approved drugs. According to the reports, which CBS News obtained under a Freedom of Information Act request, the first (filed in July 2026) described a 41-year-old woman with obesity who went into cardiac arrest, with retatrutide listed as a “suspect product” obtained from an unreliable source; the second (received in September 2026) described a 49-year-old who died after severe dehydration, malnutrition and cardiac arrest, having bought retatrutide from an online peptide vendor. Separately, CBS reported figures from America’s Poison Centers showing exposures to products sold as retatrutide rising across 2026: 249 in the first three months, 460 in the subsequent three-month period, and 862 in the three months ending September 2026.

Important limitations: the products involved were not confirmed to contain retatrutide, CBS reported that it could not verify the reports, and the FDA declined to say whether it had verified them. A FAERS report records a suspected association and does not establish that a product caused an event. Harvard Medical School’s Pieter Cohen, quoted by CBS, called the situation “concerning” and said that “if the FDA is not aggressively investigating these cases, that’s deeply concerning.” This is investigative secondary reporting of safety-surveillance data, not peer-reviewed evidence or a formal regulatory action, and it concerns unapproved products obtained for human use — not any product supplied for laboratory research. No clinical benefit or safety conclusion about retatrutide should be inferred from it.

Source: CBS News investigation (October 13, 2026; underlying data from FDA FAERS and America’s Poison Centers) · Gizmodo (secondary coverage, October 14, 2026)

AnalysisDutch reporting describes a growing black market; the Netherlands’ health inspectorate issues a public warning

Dutch outlet NL Times, summarising reporting by De Telegraaf on October 19, 2026, described a growing black market for retatrutide in the Netherlands, where the drug — which is not approved for the European market — is sold mainly as a “research peptide” powder through social-media accounts. The report states that the Dutch Health and Youth Care Inspectorate (IGJ) has issued a public warning that people in the Netherlands have been hospitalised, and some have died, after using illegal medication, and advises obtaining medicines only through a licensed pharmacy. It also notes that the European Medicines Agency has not received a marketing-authorisation application for retatrutide because the drug is still experimental, and quotes a clinician cautioning that buyers cannot know what the purchased containers actually contain. This is news reporting alongside a general public-health warning, not a retatrutide-specific enforcement action or new clinical evidence.

Source: NL Times (October 19, 2026, summarising De Telegraaf)

AnalysisNo new peer-reviewed publication, company release, or regulatory action this week

A review of clinical-trial readouts, peer-reviewed journals (via PubMed), regulator notices (FDA, Health Canada, EMA), scientific conferences, and Eli Lilly’s investor releases identified no new retatrutide trial data, peer-reviewed publication, or formal regulatory action in the seven days to October 19, 2026. The most recent citable peer-reviewed datasets remain TRIUMPH-1 in the New England Journal of Medicine and TRIUMPH-2 in The Lancet (both late September 2026), alongside TRANSCEND-T2D-1 in The Lancet (June 2026); the cardiovascular- and kidney-outcomes trial TRIUMPH-Outcomes has not reported, and TRANSCEND-CKD has reported only its design and baseline characteristics. Retatrutide remains investigational and unapproved everywhere, and Lilly’s stated plan to file for FDA approval in 2027 is unchanged.

Source: PubMed (retatrutide, by date) · Eli Lilly investor news

AnalysisThis week’s coverage was downstream reporting of the EASD TRIUMPH-2 data, not new evidence

Trade and specialist outlets continued to report on the Phase 3 TRIUMPH-2 results presented at the EASD Annual Meeting in Milan and published in The Lancet on September 30, 2026. A representative example, dated October 9, 2026, restated the trial’s already-published 80-week weight-loss and HbA1c outcomes — shown with full estimand labels in the week of October 5 entry below — and set them alongside separately published survodutide data from a different trial. No new retatrutide efficacy, safety, or discontinuation figures were reported; this is secondary coverage of an already-logged peer-reviewed dataset, not new evidence.

Source: TCTMD (secondary coverage, October 9, 2026)

AnalysisNo new trial, publication, or regulatory developments in the past seven days

A review of clinical-trial readouts, peer-reviewed journals (via PubMed), regulator notices (FDA, Health Canada, EMA), scientific conferences, and Eli Lilly’s investor releases identified no substantive new retatrutide development in the seven days to October 12, 2026. The most recent citable peer-reviewed datasets remain TRIUMPH-1 in the New England Journal of Medicine and TRIUMPH-2 in The Lancet (both late September 2026), alongside TRANSCEND-T2D-1 in The Lancet (June 2026). The cardiovascular- and kidney-outcomes trial TRIUMPH-Outcomes has not reported, and TRANSCEND-CKD has reported only its design and baseline characteristics. Retatrutide remains investigational and unapproved everywhere, and Lilly’s stated plan to file for FDA approval in 2027 is unchanged.

Source: PubMed (retatrutide, by date) · Eli Lilly investor news

Peer-reviewedTRIUMPH-1, the pivotal obesity trial, published in the New England Journal of Medicine

The full results of TRIUMPH-1 were published in the New England Journal of Medicine (NEJMoa2604169) on September 29, 2026 — the first time this pivotal Phase 3 obesity trial’s data has appeared in a peer-reviewed journal rather than a company release. In 2,339 adults with obesity or overweight and without diabetes, retatrutide reduced body weight at 80 weeks by an average of 19.0% (47.2 lb) at 4 mg, 25.9% (64.4 lb) at 9 mg, and 28.3% (70.3 lb) at 12 mg on the efficacy estimand (the effect estimated if all participants had remained on treatment), per Lilly’s corresponding results release; the treatment-regimen estimand, measured across all randomised participants, is lower. The trial also reported reductions in knee-osteoarthritis pain (WOMAC pain subscale down by up to 4.3 points, 73.1%, from a baseline of 6.0) and in obstructive sleep apnea (apnea–hypopnea index down by up to 36.1 events/hour, 60.6%, from a baseline of 58.6). Discontinuation due to adverse events rose with dose, reaching 11.3% at 12 mg versus 4.9% on placebo, with gastrointestinal events most common. The frequently circulated 30.3% figure is from a pre-specified 104-week extension in the subgroup with BMI ≥35 who continued, not the 80-week result in the full population.

Source: New England Journal of Medicine, NEJMoa2604169 · Eli Lilly results release

Peer-reviewedTRIUMPH-2 (obesity with type 2 diabetes) published in The Lancet and presented at EASD 2026

TRIUMPH-2 was published in The Lancet and presented at the 62nd EASD Annual Meeting in Milan on September 30, 2026. In 1,152 adults with obesity or overweight and type 2 diabetes (baseline mean weight 106.4 kg; baseline A1C 7.7%), retatrutide reduced body weight at 80 weeks by 12.7% (29.8 lb) at 4 mg, 19.1% (45.4 lb) at 9 mg, and 20.8% (49.6 lb) at 12 mg versus 4.0% (9.3 lb) on placebo, on the efficacy estimand; among participants with a baseline BMI ≥35, the 12 mg arm averaged 23.4% (60.8 lb). On the treatment-regimen estimand (all randomised participants), the 12 mg reduction was about 18.8% versus about 5.1% on placebo, as reported in The Lancet. A1C fell by 1.4, 1.6, and 1.5 percentage points at 4, 9, and 12 mg versus 0.2 on placebo (efficacy estimand), with up to 40% of participants reaching A1C below 5.7%. Discontinuation due to adverse events was 3.8% (4 mg), 11.6% (9 mg), and 7.7% (12 mg) versus 4.9% on placebo; gastrointestinal events were most common, and dysesthesia occurred in 4.5–7.3% of treated participants versus 0.7% on placebo. These figures had previously been released by Lilly only as topline company data (logged in the weeks of July 20 and September 28 below).

Source: Eli Lilly results release, September 29, 2026 · The Lancet · PubMed PMID 42810372

AnalysisNo new regulatory action; the peer-reviewed evidence base widens

With TRIUMPH-1 and TRIUMPH-2 now peer-reviewed, three Phase 3 datasets have cleared peer review, alongside TRANSCEND-T2D-1 in The Lancet (June 2026). A review of regulator notices (FDA, Health Canada, EMA) and Eli Lilly’s investor releases identified no new regulatory action in the seven days to October 7, 2026, and the cardiovascular-outcomes trial TRIUMPH-Outcomes has not reported. Retatrutide remains investigational and unapproved everywhere, Lilly’s stated plan to file for FDA approval in 2027 is unchanged, and in Canada retatrutide has no Drug Identification Number and may not be sold or marketed for human use.

Source: PubMed (retatrutide, by date) · Eli Lilly investor news

Company releaseLilly discloses TRIUMPH-2 efficacy-estimand weight-loss and A1C figures ahead of EASD

In an investor release dated September 15, 2026, Eli Lilly reported that retatrutide delivered up to an average of 22.5 kg (49.6 lb; 20.8%) weight loss and up to an average 1.6% A1C reduction at 80 weeks in the Phase 3 TRIUMPH-2 trial, in adults with obesity or overweight and type 2 diabetes. Lilly stated these are efficacy-estimand results, which the release defined as “efficacy had all randomized participants remained on study intervention (with possible dose interruptions and modifications) without initiating prohibited weight management treatments (and glycemic rescue therapy for glycemic endpoints only).” The release did not disclose the corresponding treatment-regimen estimand figure, nor arm-by-arm safety or discontinuation rates. These are company-reported topline figures, not peer-reviewed. TRIUMPH-2’s topline success was first announced on July 23, 2026 (logged in the week of July 20 entry below); this September 15 release is the first company statement to attach specific efficacy-estimand figures to the trial.

Source: Eli Lilly investor release, September 15, 2026 · PR Newswire

ConferenceEASD 2026 opens in Milan; retatrutide TRIUMPH-2 symposium set for September 30

The 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) opened in Milan, Italy, on September 28, 2026, and runs through October 2. Lilly’s retatrutide TRIUMPH-2 data is scheduled for an EASD-sponsored symposium on Wednesday, September 30, 2026, at 8:30–9:30 a.m. CEST. As of September 28, the full TRIUMPH-2 dataset had not yet been presented at the meeting; this page will report the presented or peer-reviewed figures once they are available.

Source: EASD 2026 · Eli Lilly investor release, September 15, 2026

AnalysisNo new peer-reviewed publication or regulatory action this week

A review of PubMed, regulator notices (FDA, Health Canada, EMA) and Eli Lilly’s investor releases identified no new peer-reviewed retatrutide publication and no new regulatory action in the seven days to September 28, 2026. The most recent citable peer-reviewed dataset remains TRANSCEND-T2D-1 in The Lancet (June 2026; PubMed PMID 42250575); the remaining Phase 3 figures across the TRIUMPH and TRANSCEND programs remain company-reported and not yet peer-reviewed, and the cardiovascular-outcomes trial TRIUMPH-Outcomes has not reported. Retatrutide remains investigational and unapproved everywhere, and Lilly’s stated plan to file for FDA approval in 2027 is unchanged.

Source: PubMed (retatrutide, by date) · Eli Lilly investor news

Company releaseLilly escalates enforcement against the illegal retatrutide market

In an investor release dated August 12, 2026, Eli Lilly called on drug regulators, customs and law-enforcement agencies, online platforms, payment processors, shipping companies and healthcare providers to help shut down the illegal sale of unapproved retatrutide. Lilly said it had referred more than 200 individuals and entities to law enforcement and regulators, identified more than 14,000 websites, advertisements, social-media posts and product listings unlawfully marketing retatrutide across more than 100 countries, and filed six new lawsuits against US sellers including compounding pharmacies and medical spas. Lilly’s chief medical officer stated that “what is being sold on the black market is not a medicine – it is entirely unverified, unapproved and not worth the risk.” This is a company enforcement statement, not new clinical evidence; retatrutide remains investigational and is not approved by Health Canada, the FDA, or any other regulator.

Source: Eli Lilly investor release, August 12, 2026 · STAT News

AnalysisNo new trial, publication, or regulatory developments in the past seven days

A review of clinical-trial readouts, peer-reviewed journals (via PubMed), regulator notices (FDA, Health Canada, EMA) and Eli Lilly’s investor releases identified no new retatrutide developments in the seven days to August 31, 2026. The most recent citable dataset remains the peer-reviewed TRANSCEND-T2D-1 publication in The Lancet (June 2026; indexed at PubMed as PMID 42250575); the remaining Phase 3 figures across the TRIUMPH and TRANSCEND programs remain company-reported and not yet peer-reviewed, and the cardiovascular-outcomes trial TRIUMPH-Outcomes has not reported. The next major scientific meeting likely to feature retatrutide data, the EASD Annual Meeting, is scheduled for September 28 – October 2, 2026, in Milan.

Source: PubMed (retatrutide, by date) · EASD 2026

AnalysisNo new data, publications, or regulatory actions this week

A review of clinical-trial readouts, peer-reviewed journals (via PubMed), regulator notices (FDA, Health Canada, EMA), scientific conferences, and Eli Lilly’s investor releases identified no substantive new retatrutide development for the week of August 10, 2026. The most recent citable dataset remains the peer-reviewed TRANSCEND-T2D-1 publication in The Lancet (June 2026); the remaining Phase 3 figures across the TRIUMPH and TRANSCEND programs remain company-reported and not yet peer-reviewed. Ongoing trade and clinical commentary continued to discuss Lilly’s August 3 expanded-access (compassionate-use) announcement, but reported no new efficacy or safety data; that development is logged in the week of August 3 entry below.

Source: Eli Lilly investor news (no new retatrutide release this week) · PubMed (retatrutide, by date)

Company statementLilly formalises a limited expanded-access program

In statements to reporters on August 3, 2026, Lilly said it would allow patients who cannot enrol in a clinical trial to request retatrutide ahead of FDA approval. A company spokesperson said: “For a limited number of patients who meet specific medical criteria and cannot enroll in a clinical trial, we believe it is medically appropriate to make authentic retatrutide available before FDA approval, consistent with FDA's guidance.” Reported eligibility criteria are: age 18 or older; severe obesity unresponsive to existing approved obesity medication; at least two serious or life-threatening obesity-related complications requiring medical care; and inability to participate in ongoing retatrutide or comparable investigational trials. This was a statement confirmed to the press rather than a formal press release or peer-reviewed report, and Lilly still plans to file for FDA approval in 2027.

Source: STAT News · Reuters (syndicated)

AnalysisClinician reaction is mixed; criteria are narrow

The move follows June 2026 STAT reporting that Lilly had granted a single 79-year-old patient compassionate-use access in April 2026, which prompted other physicians — including Spencer Nadolsky and Mike Albert — to say their own access requests had gone weeks without a substantive response. Coverage this week noted the published criteria are strict enough that most patients seeking the drug would not qualify. No clinical outcome from any expanded-access use has been reported, and none should be inferred; this is an access-policy development, not new trial evidence.

Source: AJMC

RegulatoryHealth Canada announces permanent injunction against Canlab Research

The Superior Court of Québec granted the injunction on June 11, 2026; Health Canada announced it publicly in late July. It permanently bars the company from selling unauthorized injectable peptides and from advertising them “including through any website or social media platform accessible with a Canadian Internet Protocol (IP) address.” Retatrutide was among the compounds named in Health Canada’s April 9, 2026 advisory.

Source: Health Canada news release · Our full analysis: FDA & Peptides in 2026

AnalysisCoverage frames the 2027 FDA filing as a delay

Following Lilly’s July 23 confirmation that it will file for FDA approval in 2027, several outlets characterised the timeline as a delay against earlier expectations. No change to the underlying data was reported; the compound remains investigational everywhere.

Source: CNBC · BioPharma Dive

Company releaseTRIUMPH-2 and TRIUMPH-3 topline results

TRIUMPH-2 (type 2 diabetes with obesity, n≈1,152) and TRIUMPH-3 (severe obesity with established cardiovascular disease, n≈1,949) reported topline results over 80 weeks, with both trials meeting their primary endpoints. See the linked source for the reported figures.

Source: Eli Lilly investor release, July 23, 2026

Company releaseCardiovascular outcome was neutral, not protective

TRIUMPH-3 recorded 44 major adverse cardiovascular events in the retatrutide arms versus 52 on placebo — a five-point MACE hazard ratio of 0.82 (95% CI 0.55–1.22). The confidence interval crosses 1.0, so the result is not statistically significant; Lilly noted events occurred less frequently than anticipated in both arms. Cardiovascular risk factors also moved in a favourable direction in the treatment arm (see source). The larger TRIUMPH-Outcomes study is designed to answer the events question.

Source: Fierce Biotech

Peer-reviewedTRANSCEND-T2D-1 published in The Lancet

TRANSCEND-T2D-1 studied 537 adults with type 2 diabetes across 48 sites over 40 weeks. As the first peer-reviewed Phase 3 retatrutide dataset, it is the single most citable reference on the compound to date; see the publication for its full glycaemic, weight and safety results. Gastrointestinal adverse events were reported as mild to moderate, with no severe hypoglycaemia.

Source: The Lancet, doi:10.1016/S0140-6736(26)00967-0 (online June 6, 2026)

ConferenceTRIUMPH-1 and TRANSCEND-T2D-1 presented at ADA 2026

Both datasets were presented at the American Diabetes Association 86th Scientific Sessions on June 6, 2026, in New Orleans; see the linked coverage for the reported secondary outcomes.

Source: Cleveland Clinic Journal of Medicine, ADA 2026 coverage

Company releaseTRIUMPH-1 topline: both estimands reported

In 2,339 randomised participants over 80 weeks, Lilly reported outcomes under both estimands; see the linked source for the full figures.

A recurring reporting error is worth noting: the widely circulated 30.3% figure comes from a pre-specified extension at 104 weeks in the 532 participants with BMI ≥35 who continued — not the whole trial population at 80 weeks.

Source: Eli Lilly release, May 21, 2026

Company releaseTolerability: discontinuation rose in the higher-strength arms

Discontinuation due to adverse events rose across the trial arms, reaching 11.3% in the highest-strength arm versus 4.9% on placebo. Nausea was the most common adverse event, alongside diarrhoea, constipation and vomiting. See the linked source for the full arm-by-arm figures.

Source: The Pharmaceutical Journal

Company releaseTRIUMPH-4: obesity and knee-osteoarthritis topline

In 445 adults with obesity or overweight plus knee osteoarthritis and without diabetes (BMI ≥27; baseline mean 112.7 kg), 68 weeks of retatrutide reported topline results across the active arms. See the linked source for the reported figures.

Source: Eli Lilly release, December 2025

Company releaseKnee pain outcomes

The trial also reported knee-pain and function (WOMAC) outcomes; see the linked source for the reported figures.

Source: Patient Care Online

AnalysisNew dysesthesia signal not seen in Phase 2

Dysesthesia — an abnormal sense of touch in which normal sensations feel unusual or painful — occurred in up to 20.9% of participants on retatrutide, versus 0.7% on placebo. Lilly reported that these events did not appear to lead to discontinuation. The signal had not emerged in Phase 2 testing. Overall discontinuation in TRIUMPH-4 reached 18.2% versus 4.0% on placebo.

Source: BioSpace